Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for heart muscle disease symptoms

NCT ID NCT02590809

Symptom relief Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a drug called BX1514M in 38 people with hypertrophic cardiomyopathy, a genetic heart condition that can cause shortness of breath, chest pain, and dizziness. The drug aims to improve blood flow by tightening veins, which may reduce blockages in the heart. Participants took the drug or a placebo for 30 days, and researchers measured how far they could walk in six minutes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BX1514M
What this could lead to
If it works, this could point toward a new treatment option for hypertrophic cardiomyopathy symptoms like shortness of breath and chest pain.
What could go wrong
This is a small, early-phase trial with only 38 people. The drug may not work better than placebo, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

38 people

The number who actually took part.

Started

Oct 2015

Finished

Jul 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a typical or atypical hypertrophic cardiomyopathy (HCM) confirmed by imaging modalities (echo and MRI) and/or genetic tests or a relative history of HCM * Left ventricular obstruction during exercise on treadmill (above 50 mmHg) * Positive response to leg lifting test (obstruction reduction above 20 mmHg) at rest or in early recovery phase * Daily symptoms as shortness of breath during exercise (NYHA2-3), non coronary chest pain, dizziness * Correct ultrasound windows quality * Sinus rhythm * Optimal medical treatment * For women, pregnancy test or contraception * Written consent form obtained Exclusion Criteria: * Previous treatment by BX1514M * Extra-cardiac pathology with life expectancy below than 1 year * No capability of consent form written * Pregnancy women * Secondary hypertension hypertrophy, secondary valvular disease hypertrophy * Permanent atrial fibrillation * Severe ventricular arrhythmia without Implantable Cardioverter Defibrillator (ICD) * Severe coronary disease * Severe non stabilized hypertension * Severe cardiopathy (ejection fraction below 40% or demonstrated elevated end diastolic pressure or pulmonary pressure above 60 mmHg) * Bradycardia * Narrow angle glaucoma * Vascular prethrombotic diseases * Vascular spams * Thyrotoxicosis * Pheochromocytoma * Severe renal failure (\<30ml/mn) * Patients at risk of urinary retention secondary to prostatic severe disease * Raynaud's disease * Non selective Monoamine Oxidase Inhibitors (MAOIs), iproniazid, nialamide or ephedrine, methylphenidate, phenylephrine, pseudoephedrine or digitalic * Procedures modifying the peripheral venous return * Participation to other research protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertrophic cardiomyopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertrophic cardiomyopathy

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.